156 related articles for article (PubMed ID: 13678646)
1. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
Hobbs AJ; Moncada S
Vascul Pharmacol; 2003 Oct; 40(3):149-54. PubMed ID: 13678646
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
3. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
4. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
5. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase.
Roger S; Paysant J; Badier-Commander C; Cordi A; Verbeuren TJ; Félétou M
Vascul Pharmacol; 2010; 53(5-6):281-7. PubMed ID: 20933607
[TBL] [Abstract][Full Text] [Related]
6. Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production.
Monteiro PF; Morganti RP; Delbin MA; Calixto MC; Lopes-Pires ME; Marcondes S; Zanesco A; Antunes E
Cardiovasc Diabetol; 2012 Jan; 11():5. PubMed ID: 22248260
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
9. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
10. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
[TBL] [Abstract][Full Text] [Related]
11. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
13. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Stasch JP; Schmidt P; Alonso-Alija C; Apeler H; Dembowsky K; Haerter M; Heil M; Minuth T; Perzborn E; Pleiss U; Schramm M; Schroeder W; Schröder H; Stahl E; Steinke W; Wunder F
Br J Pharmacol; 2002 Jul; 136(5):773-83. PubMed ID: 12086987
[TBL] [Abstract][Full Text] [Related]
14. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
15. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
Kempfert J; Behrends S
Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
[TBL] [Abstract][Full Text] [Related]
16. Preserved activity of soluble guanylate cyclase (sGC) in iliac artery from middle-aged rats: Role of sGC modulators.
Justo AFO; de Oliveira MG; Calmasini FB; Alexandre EC; Bertollotto GM; Jacintho FF; Antunes E; Mónica FZ
Nitric Oxide; 2021 Jan; 106():9-16. PubMed ID: 33122152
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological stimulation of soluble guanylate cyclase modulates hypoxia-inducible factor-1alpha in rat heart.
Tsuruda T; Hatakeyama K; Masuyama H; Sekita Y; Imamura T; Asada Y; Kitamura K
Am J Physiol Heart Circ Physiol; 2009 Oct; 297(4):H1274-80. PubMed ID: 19684186
[TBL] [Abstract][Full Text] [Related]
19. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.
Nakane M; Kolasa T; Chang R; Miller LN; Moreland RB; Brioni JD
J Pharmacol Sci; 2006 Oct; 102(2):231-8. PubMed ID: 17050951
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
